NGM Biopharmaceuticals, Inc.
NGM Biopharmaceuticals, Inc.（NGM）内幕交易
基于 SEC Form 4 的买入/卖出笔数、买卖比与情绪标签；可在本季度与近12个月之间切换；下方为季度图与交易明细。
SEC EDGAR · FMP · NGM · 截至 2026年6月9日
活动摘要
买入笔数
10
P-Purchase only
卖出笔数
0
近12个月
买卖比
∞
Buy/Sell (by trades)
整体情绪
NGM Biopharmaceuticals, Inc.内部人在过去近12个月净买入股份，可能反映对公司前景的信心。
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 买入仅计P-Purchase · 卖出仅计S-Sale
截至 2026年6月9日
NGM 季度内部人买卖趋势
NGM 内幕交易卖出 · NGM 内幕交易买入 · 季度活动
Mobile shows last 4Q · Desktop shows full 8Q
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 最近8季度
As of Jun 9, 2026
近期内幕交易记录
NGM 高管卖出股份 · NGM 董事内幕交易 · SEC Form 4申报
横向滑动查看全部列
| 日期 | 内部人 | 类型 | 股数 | 总金额 | 申报 |
|---|---|---|---|---|---|
| Apr 5, 2024 | TCG Opportunity III GP, LLC 10 percent owner | Other | 1,000 | — | Form 4 |
| Apr 5, 2024 | TCG Opportunity III GP, LLC 10 percent owner | Other | 44,000 | — | Form 4 |
| Apr 5, 2024 | COLUMN GROUP GP, LP 10 percent owner | Other | 1,000 | — | Form 4 |
| Apr 5, 2024 | COLUMN GROUP GP, LP 10 percent owner | Other | 44,000 | — | Form 4 |
| Apr 5, 2024 | COLUMN GROUP L P Director | Other | 1,000 | — | Form 4 |
| Apr 5, 2024 | COLUMN GROUP L P Director | Other | 44,000 | — | Form 4 |
| Apr 5, 2024 | GOEDDEL DAVID V Director | Other | 1,000 | — | Form 4 |
| Apr 5, 2024 | GOEDDEL DAVID V Director | Other | 100,000 | — | Form 4 |
| Apr 5, 2024 | Pierce Valerie L See Remarks | Other | 26,458 | $41K | Form 4 |
| Apr 5, 2024 | RIEFLIN WILLIAM JL Director | Other | 2,769,168 | — | Form 4 |
| Apr 5, 2024 | Viret Jean-Frederic CFO | Other | 3,038 | $5K | Form 4 |
| Apr 5, 2024 | WOODHOUSE DAVID J CEO · Director | Other | 23,993 | $37K | Form 4 |
| Apr 5, 2024 | WOODHOUSE DAVID J CEO · Director | Other | 97,654 | — | Form 4 |
| Apr 5, 2024 | Perlich Irene PAO | Other | 6,284 | $10K | Form 4 |
| Apr 5, 2024 | Hooper Suzanne Sawochka Director | Other | 7,000 | $11K | Form 4 |
| Apr 5, 2024 | Lieu Hsiao D Chief Medical Officer | Other | 19,349 | $30K | Form 4 |
| Jan 16, 2024 | Lieu Hsiao D EVP, CHIEF MEDICAL OFFICER | Other | 5,430 | $7K | Form 4 |
| Jan 16, 2024 | Perlich Irene PRINCIPAL ACCOUNTING OFFICER | Other | 1,025 | $1K | Form 4 |
| Jan 16, 2024 | Pierce Valerie L SVP, GC & CCO | Other | 5,021 | $7K | Form 4 |
| Jan 16, 2024 | WOODHOUSE DAVID J CHIEF EXECUTIVE OFFICER · Director | Other | 13,032 | $17K | Form 4 |
| Nov 16, 2023 | COLUMN GROUP L P Director | Purchase | 5,840 | $4K | Form 4 |
| Nov 15, 2023 | COLUMN GROUP L P Director | Purchase | 16,791 | $12K | Form 4 |
| Nov 16, 2023 | GOEDDEL DAVID V Director | Purchase | 5,840 | $4K | Form 4 |
| Nov 15, 2023 | GOEDDEL DAVID V Director | Purchase | 16,791 | $12K | Form 4 |
| Nov 16, 2023 | GOEDDEL DAVID V Director | Purchase | 1,460 | $907 | Form 4 |
WOODHOUSE DAVID J
CHIEF EXECUTIVE OFFICER · Director
日期
Jan 16
股数
13,032
均价
$1.34
总金额
$17K
⚡ = 金额≥$100万 · Award/Option价格显示— · 仅Form4 · 仅普通股
▸ 数据来源：SEC EDGAR · Form 4 申报 · ⚡ = 金额≥$100万 · Award/Option 价格显示 —
关于 NGM 内幕交易
NGM 内幕交易
NGM Biopharmaceuticals, Inc.（NGM）内幕交易数据来源于公司内部人（包括NGM）提交的SEC Form 4申报文件。过去12个月内，0位内部人向SEC提交了交易申报。NGM内部人近期主要在买入，这可能反映预设的10b5-1计划执行，而非方向性判断。
如需查看NGM Biopharmaceuticals, Inc.机构持仓比例和内部人持股百分比，请访问持仓（Ownership）标签页 → Ownership tab →
常见问题
NGM 内幕交易 · 5个问题NGM Biopharmaceuticals, Inc.（NGM）的内部人包括高管和董事，如NGM等。过去12个月内，0位内部人向SEC提交了Form 4交易申报。内部人须在交易日期后2个工作日内完成申报。
▸ 数据来源：FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · RSU归属不计入情绪 · As of Jun 9, 2026